LentiVector® Platform

Oxford Biomedica’s LentiVector^® platform, the first and leading commercial lentiviral-based gene delivery system, enables the successful development of breakthrough gene and cell-based medicines.

We have a long and broad clinical and commercial track record in the gene therapy field spanning over 20 years. Our data demonstrates over seven years of stable, dose dependent gene expression in patients after direct in vivo administration. Thousands of patients have safely received ex vivo and in vivo treatment with therapies that use our vectors.

Our LentiVector^® platform has delivered the first FDA and EMA approved CAR-T cell therapy.